The present invention is directed to a method for treating solid cancer in patients with clonal hematopoiesis of indeterminate potential (CHIP). The method introduces a therapeutic intervention of dapansutrile to improve the treatment of a solid cancer, such as breast cancer, in a CHIP patient. The method includes first determining whether a patient has a CHIP condition by detecting the presence or absence of Tet2 or DNMT3A mutation from a biological sample of the patient, and then followed by a therapeutic intervention with dapansutrile in patients having a CHIP condition. This application shows a role for CHIP in driving breast cancer. The data provide a rationale for Tet2 or DNMT3A mutation screening in breast cancer patients and offer dapansutrile as a therapeutic treatment.
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
The present invention provides a method for treating pancreatic cancer. The method comprises administering to a subject in need thereof an effective amount of dapansutrile. Preferred route of administration of dapansutrile is oral administration. The present invention also provides a combination treatment of pancreatic cancer, by administering dapansutrile and gemcitabine to the patient in need thereof.
The present invention is directed to a method for treating Parkinson's disease. The method comprises administering to a subject in need thereof dapansutrile, in an effective amount. Dapansutrile minimizes the clinical features of PD such as locomotor impairments through the modulation of the inflammatory response, reduction in α-synuclein levels, and protection of dopaminergic neurons. A preferred route of administration is oral administration.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
The present invention is directed to a method for treating spinal cord injury. The method comprises administering to a subject in need thereof 3-methanesulfonylpropionitrile (dapansutrile), or a pharmaceutically acceptable solvate thereof, in an effective amount. The preferred route of administration is oral administration.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
C07C 317/28 - SulfonesSulfoxydes ayant des groupes sulfone ou sulfoxyde et des atomes d'azote, ne faisant pas partie de groupes nitro ou nitroso, liés au même squelette carboné avec des groupes sulfone ou sulfoxyde liés à des atomes de carbone acycliques du squelette carboné
5.
METHOD FOR PREVENTING OR TREATING LUNG INFECTION AND LUNG INFLAMMATION
The present invention is directed to a method for preventing or treating lung infection and/or lung inflammation. The present invention provides a method for preventing or treating macrophage activation syndrome in an infected patient. The present invention also provides a method preventing or treating pneumonitis. The present invention further provides a method for treating COVID-19 patients with SAR-CoV-2 viral infection having mild or moderate respiratory symptoms or fever. The method comprises administering to a subject in need thereof dapansutrile, or a pharmaceutically acceptable solvate thereof, in an effective amount. The present method treats early cytokine release syndrome and arrests the initiation of the IL-1β and IL-18 mediated "cytokine storm" and/or pneumonitis in a patient, without causing a negative effect to his heart condition, type II diabetes, and other issues. Oral administration is a preferred route of administration.
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
The present invention is directed to a method for treating diabetes. The method comprises administering to a subject in need thereof dapansutrile, or a pharmaceutically acceptable solvate thereof, in an effective amount. Oral administration is a preferred route of administration.
The present invention is directed to a method of treating breast cancer. The method comprises administering to a subject in need thereof an effective amount of dapansutrile, or a pharmaceutically acceptable solvate thereof. The method optionally comprises further administering to the subject an effective amount of a checkpoint inhibitor.
A61K 31/4709 - Quinoléines non condensées contenant d'autres hétérocycles
A61K 31/541 - Thiazines non condensées contenant d'autres hétérocycles
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
The present invention is directed to a method for treating Asthma. The method comprises administering to a subject in need thereof 3-methanesulfonylpropionitrile (dapansutrile), or a pharmaceutically acceptable solvate thereof, in an effective amount. The preferred route of administration is oral administration or local administration.
A61P 11/04 - Médicaments pour le traitement des troubles du système respiratoire des maux de gorge
C07C 317/26 - SulfonesSulfoxydes ayant des groupes sulfone ou sulfoxyde et des atomes d'azote, ne faisant pas partie de groupes nitro ou nitroso, liés au même squelette carboné
C07C 317/28 - SulfonesSulfoxydes ayant des groupes sulfone ou sulfoxyde et des atomes d'azote, ne faisant pas partie de groupes nitro ou nitroso, liés au même squelette carboné avec des groupes sulfone ou sulfoxyde liés à des atomes de carbone acycliques du squelette carboné
C07C 317/48 - SulfonesSulfoxydes ayant des groupes sulfone ou sulfoxyde et des groupes carboxyle liés au même squelette carboné le squelette carboné étant substitué de plus par des atomes d'azote liés par des liaisons simples, ne faisant pas partie de groupes nitro ou nitroso
C07C 317/50 - SulfonesSulfoxydes ayant des groupes sulfone ou sulfoxyde et des groupes carboxyle liés au même squelette carboné le squelette carboné étant substitué de plus par des atomes d'azote liés par des liaisons simples, ne faisant pas partie de groupes nitro ou nitroso au moins un des atomes d'azote faisant partie de l'un des groupes X étant un hétéro-atome, Y étant un atome quelconque
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Analgesics; Anti-inflammatories; Anti-inflammatory pharmaceuticals; Anti-inflammatory preparations and chemical compounds; Pharmaceutical preparations and products for the prevention of diseases, namely, inflammatory disorders and conditions; Pharmaceutical preparations and products for the prevention of diseases, namely, pain in humans and animals; Pharmaceutical preparations and substances for the treatment of inflammatory disorders and diseases; Therapeutic pharmaceutical preparations and substances for the treatment of pain and inflammation; Pharmaceutical preparations and products for medical purposes for treating inflammatory disorders and conditions in humans and animals
The present invention is directed to a method for preventing and/or treating melanoma such as superficial spreading melanoma, nodular melanoma, lentigo maligna melanoma, and acral lentiginous melanoma. The method comprises administering to a subject in need thereof an effective amount of dapansutrile. The method optionally comprising co-administering anti-PD-1 antibody with dapansutrile. A preferred route of administration is oral administration.
The present invention is directed to a method for preventing and/or treating Alzheimer's disease. The method comprises administering to a subject in need thereof an effective amount of dapansutrile. The method reduces neuroinflammation and improves the cognitive functions such as learning and memory processes of the subject. Dapansutrile can be administered to the subject orally at a dose of 100-2000 mg/day for 3 months to 5 years or longer.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
The present invention is directed to a method for treating Schnitzler's syndrome. The method comprises administering to a subject in need thereof dapansutrile, or a pharmaceutically acceptable solvate thereof, in an effective amount. Oral administration is a preferred route of administration.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Analgesics; Anti-inflammatories; Anti-inflammatory pharmaceuticals; Anti-inflammatory preparations and chemical compounds; Pharmaceutical preparations and products for the prevention of diseases, namely, inflammatory disorders and conditions; Pharmaceutical preparations and products for the prevention of diseases, namely, pain in humans and animals; Pharmaceutical preparations and substances for the treatment of inflammatory disorders and diseases; Therapeutic pharmaceutical preparations and substances for the treatment of pain and inflammation; Pharmaceutical preparations and products for medical purposes for treating inflammatory disorders and conditions in humans and animals
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Analgesics; Anti-inflammatories; Anti-inflammatory pharmaceuticals; Anti-inflammatory preparations and chemical compounds; Pharmaceutical preparations and products for the prevention of diseases; Pharmaceutical preparations and substances for the treatment of inflammatory disorders and diseases; Therapeutic pharmaceutical preparations and substances for the treatment of pain and inflammation; Pharmaceutical preparations and products for medical purposes for treating inflammatory disorders and conditions in humans and animals.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Analgesics; Anti-inflammatories; Anti-inflammatory pharmaceuticals; Anti-inflammatory preparations and chemical compounds; Pharmaceutical preparations and products for the prevention of diseases, namely, inflammatory disorders and conditions; Pharmaceutical preparations and products for the prevention of diseases, namely, pain in humans and animals; Pharmaceutical preparations and substances for the treatment of inflammatory disorders and diseases; Therapeutic pharmaceutical preparations and substances for the treatment of pain and inflammation; Pharmaceutical preparations and products for medical purposes for treating inflammatory disorders and conditions in humans and animals
The present invention is directed to a method for treating cardiovascular diseases such as acute myocardial infarction, atherosclerosis, heart failure, stroke, thrombosis, carditis (including acute myocarditis, acute pericarditis and complicated pericarditis), cardiac allograft rejection, cardiomyopathy, and peripheral vascular diseases. The method comprises administering to a subject in need thereof dapansutrile, in an effective amount. A preferred route of administration is oral administration.
The present invention is directed to a method for treating multiple sclerosis by administering dapansutrile to a subject in need thereof. A preferred route of administration is oral administration.
The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and 4-benzylsulfonyl-2-butenenitrile, or a pharmaceutically acceptable salt or solvate thereof. The present invention is directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering 4-benzylsulfonyl-2-butenenitrile, or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.
The present invention is directed to 4-methylsulfonyl-2-butenenitrile, or a pharmaceutically acceptable salt, an isomer, or isomers thereof. The present invention is also directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and 4-methylsulfonyl-2-butenenitrile, or a pharmaceutically acceptable salt, an isomer, or isomers thereof. The present invention is directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering 4-methylsulfonyl-2-butenenitrile, or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.
C07C 317/26 - SulfonesSulfoxydes ayant des groupes sulfone ou sulfoxyde et des atomes d'azote, ne faisant pas partie de groupes nitro ou nitroso, liés au même squelette carboné
22.
PHARMACEUTICAL USE OF 3-BENZYLSULFONYLPROPIONITRILE
The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and 3-benzylsulfonylpropionitrile, or a pharmaceutically acceptable salt thereof. The present invention is directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering 3-benzylsulfonylpropionitrile, or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.
C07C 317/32 - SulfonesSulfoxydes ayant des groupes sulfone ou sulfoxyde et des atomes d'azote, ne faisant pas partie de groupes nitro ou nitroso, liés au même squelette carboné avec des groupes sulfone ou sulfoxyde liés à des atomes de carbone de cycles aromatiques à six chaînons du squelette carboné
23.
3, 4-BIS-BENZYLSULFONYLBUTANENITRILE AND ITS PHARMACEUTICAL USE
The present invention is directed to 3, 4-bis-benzylsulfonylbutanenitrile, or a pharmaceutically acceptable salt, an enantiomer, or enantiomers thereof. The present invention is also directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and 3, 4-bis-benzylsulfonylbutanenitrile, or a pharmaceutically acceptable salt, an enantiomer, or enantiomers thereof. The present invention is further directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering 3, 4-bis-benzylsulfonylbutanenitrile, or a pharmaceutically acceptable salt, an enantiomer, or enantiomers thereof to a subject in need thereof.
A01N 37/12 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés organiques comportant un atome de carbone possédant trois liaisons à des hétéro-atomes, avec au plus deux liaisons à un halogène, p. ex. acides carboxyliques contenant le groupe , dans lequel Cn représente un squelette carboné ne comportant pas de cycleLeurs thio-analogues
C07C 315/00 - Préparation de sulfonesPréparation de sulfoxydes
24.
PHARMACEUTICAL COMPOSITION AND USE OF DIETHYL (2-CYANOETHYL)PHOSPHONATE
The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and diethyl (2-cyanoethyl)phosphonate, or a pharmaceutically acceptable salt thereof. The present invention is directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering diethyl (2-cyanoethyl)phosphonate, or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
(1) Providing medical and scientific research information in the fields of pharmaceuticals and clinical trials; pharmaceutical research services; pharmaceutical research and development; pharmaceutical product evaluation and development; conducting early evaluations in the field of new pharmaceuticals
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Providing medical and scientific research information in the fields of pharmaceuticals and clinical trials; pharmaceutical research services; pharmaceutical research and development; pharmaceutical product evaluation and development; conducting early evaluations in the field of new pharmaceuticals
